Hypophosphatemia: Clinical Consequences and Management

Steven M. Brunelli*† and Stanley Goldfarb*

*Renal-Electrolyte and Hypertension Division, Department of Medicine, and †Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

ABSTRACT

Current evidence regarding the clinical consequences of hypophosphatemia is not straightforward. Given the potentially different implications of hypophosphatemia among various patient groups, this commentary touches on patients with low serum phosphate after acute hospitalization, those with chronic ambulatory hypophosphatemia, and those with hypophosphatemia in the setting of advanced renal disease. Finally, this commentary examines the evidence regarding how best to replete phosphorous in the hypophosphatemic patient.


Although rare in the general population, the incidence of hypophosphatemia is high in certain subgroups of patients, such as those who are hospitalized (2.2 to 3.1%) or admitted to intensive care units (28.85 to 33.9%), and those with sepsis (65 to 80%), chronic alcoholicism (2.5 to 30.4%), major trauma (75%), and chronic obstructive pulmonary disease (21.5%). So what are the potential clinical consequences of hypophosphatemia, and how should one replete phosphate? Because the physiologic consequences of hypophosphatemia are likely different among different groups of patients, our commentary considers patients with hypophosphatemia after acute hospitalization, those with chronic ambulatory hypophosphatemia, and those who demonstrate hypophosphatemia in the setting of advanced kidney disease.

When first examined in the 1970s, patients who received phosphate-free hyperalimentation manifested severe hypophosphatemia (<0.3 mmol/L [1 mmol/L = 3.125 mg/dl]) and developed acute hemolytic anemia as a result of reduced erythrocyte cell membrane deformability and life span, resulting probably from intracellular ATP depletion. A similar syndrome was described in chronic alcoholics with rhabdomyolysis. In current clinical practice, instances of dramatic hypophosphatemia are rare compared with hypophosphatemia of lesser magnitude and shorter duration, and the clinical consequences of the latter circumstance are much less certain.

The association between hypophosphatemia and mortality among hospitalized patients is outlined in Table 1. Despite variations in the underlying patient cohorts, definitions of hypophosphatemia, and study designs, the results of these studies consistently demonstrated an association between hypophosphatemia and in-hospital mortality. However, none of these studies adjusted for potential confounding on the basis of demographic factors, comorbid disease state, or nutritional status, thus leaving in question the potential for causality.

The role of hypophosphatemia as a determinant of left ventricular function in ambulatory patients was first popularized by manufactured associations between hypophosphatemia and markers of poor respiratory, cardiovascular, and postoperative outcomes, these studies also fail to adjust for confounding variables. Inconsistent definitions of hypophosphatemia across studies, use of invalidated outcome surrogates, and issues of multiple comparisons further obscure conclusions. Overall evidence demonstrates an association between hypophosphatemia and poor clinical outcomes among hospitalized patients, suggesting that hypophosphatemia is an adverse prognostic marker. However, the data cannot determine potential causality.

Given the commonplace clinical overlap between the two syndromes, hypophosphatemia among patients with diabetic ketoacidosis (DKA) warrants special consideration. A randomized controlled trial demonstrated that among patients who presented with DKA, phosphate supplementation did not improve biochemical or clinical outcomes, and it was associated with lower ionized calcium. On the basis of these findings, routine repletion of phosphate in patients who present with DKA is probably not warranted.
CLINICAL COMMENTARY

Table 1. Association between hypophosphatemia and mortality among hospitalized patients

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Underlying Patient Population</th>
<th>Definition of HP</th>
<th>n</th>
<th>Outcome Measure (HP versus Controls)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case-control</td>
<td>Hospitalized; &gt;65 yr old</td>
<td>≤0.77 mmol/L</td>
<td>325</td>
<td>OR in-hospital mortality</td>
<td>2.79 (2.0 to 3.89)</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>Hospitalized patients</td>
<td>≤0.33 mmol/L</td>
<td>10,197</td>
<td>Incidence of in-hospital mortality</td>
<td>18.2 versus 4.6% (P &lt; 0.001)</td>
</tr>
<tr>
<td>Prospective cohort</td>
<td>Surgical critical care</td>
<td>LLN</td>
<td>60 HP, 148 controls</td>
<td>Incidence of in-hospital mortality</td>
<td>30 versus 15.2% (P &lt; 0.05)</td>
</tr>
<tr>
<td>Matched case-control</td>
<td>Septic patients</td>
<td>≤0.32 mmol/L</td>
<td>26 HP, 29 controls</td>
<td>OR in-hospital mortality</td>
<td>7.98 (2.3 to 27.6)</td>
</tr>
</tbody>
</table>

aHP, hypophosphatemia; LLN, lower limit of normal; OR, odds ratio.
bPoint estimate (95% confidence interval).

Table 2. Association between HP and surrogate outcome measures

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Underlying Patient Population</th>
<th>Definition of HP</th>
<th>n</th>
<th>Outcome Measure (HP versus Controls)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-sectional</td>
<td>Hospitalized general medical</td>
<td>≤0.8 mmol/L</td>
<td>23 HP, 11 controls</td>
<td>Prevalence of respiratory muscle weakness</td>
<td>70 versus 0% (P &lt; 0.001)</td>
</tr>
<tr>
<td>Prospective cohort</td>
<td>Surgical critical care</td>
<td>Fall ≥0.05 to absolute level ≤0.21 mmol/L</td>
<td>21 HP, 41 controls</td>
<td>Duration of mechanical ventilation</td>
<td>10.5 ± 5.2 versus 7.1 ± 2.8 (P = 0.04)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Duration of hospitalization</td>
<td>12.1 ± 7.1 versus 8.2 ± 4.6 (P = 0.01)</td>
</tr>
<tr>
<td>Crossover</td>
<td>Septic shock</td>
<td>&lt;0.64 mmol/L</td>
<td>10</td>
<td>LV stroke work index</td>
<td>23.8 ± 10 versus 27.5 ± 8.5g/m² (P &lt; 0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Systolic BP</td>
<td>114 ± 14 versus 129 ± 20 mmHg (P &lt; 0.01)</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>After hepatectomy</td>
<td>&lt;0.48 mmol/L on POD 15</td>
<td>15</td>
<td>Incidence of postoperative complications</td>
<td>60 versus 16% (P &lt; 0.001)</td>
</tr>
<tr>
<td>Retrospective cohort</td>
<td>Hepatic lobectomy or cryosurgery</td>
<td>&lt;0.8 mmol/L</td>
<td>21 HP, 14 control</td>
<td>Incidence of postoperative complications</td>
<td>80 versus 28% (P &lt; 0.05)</td>
</tr>
<tr>
<td>Crossover</td>
<td>Mechanically ventilated patients</td>
<td>Mean phosphate 0.55 mmol/L</td>
<td>8</td>
<td>Stimulated transdiaphragmatic pressure</td>
<td>9.75 ± 3.8 versus 17.25 ± 6.5 cmH₂O (P &lt; 0.001)</td>
</tr>
<tr>
<td>Prospective cohort</td>
<td>Coronary care unit patients after MI</td>
<td>&lt;0.83 mmol/L</td>
<td>38 HP, 73 controls</td>
<td>Incidence of ventricular tachycardia</td>
<td>57 versus 27% (P = 0.007)</td>
</tr>
</tbody>
</table>

aLV, left ventricular; MI, myocardial infarction; POD, postoperative day.
bMean ± SD before versus after phosphate repletion.
cMean ± SD.

ized by Darsee et al. in the 1970s, who reported dramatic improvement in left ventricular function in three patients with hypophosphatemia after phosphate repletion. Subsequent allegations that these data were fraudulent called into question the relationship between serum phosphate and cardiac function. A prospective cohort study in which left ventricular function was compared among groups of patients with moderate (0.45 mmol/L) and severe (0.29 mmol/L) hypophosphatemia and normophosphatemic control subjects was conducted later. Correction of hypophosphatemia resulted in improved left ventricular performance in severe but not in mild hypophosphatemia. However, none of the patients in any group had clinically overt heart failure at baseline. In addition, children who had X-linked hypophosphatemic rickets and in whom hypophosphatemia (mean 0.83 ± 0.16 mmol/L) was induced by withholding phosphate and vitamin D supplements demonstrated normal echocardiographic measurements of left ventricular performance. To our knowledge, no analytic studies of the relationship between cardiac function and hypophosphatemia using clinical endpoints have been conducted. The conflicting evidence in studies that used surrogate markers emphasizes the need for such investigations.
obesity, and the metabolic syndrome. One trial demonstrated that patients with chronic hypophosphatemia had a propensity for glucose intolerance in both euglycemic and hyperglycemic states as compared with normophosphatemic control subjects. Furthermore, among patients with a family history of type 2 diabetes, serum phosphate levels were significantly negatively correlated with glucose tolerance. Data also indicate significant negative correlations between serum phosphate and body mass index and waist-to-hip ratio. Among patients who entered a lifestyle modification program for cardiovascular risk reduction, serum phosphate was significantly negatively correlated with systolic BP. Taken together, these findings favor an association between hypophosphatemia and glucose intolerance, obesity, and other manifestations of the metabolic syndrome. Adequate data do not exist, however, to warrant phosphate repletion in patients with hypophosphatemia on the basis of improving glucose tolerance or cardiovascular risk profile.

Grounds also exist to suspect an association between hypophosphatemia and short stature and poor bone health. Chronic hypophosphatemia in general pediatric populations is exceedingly rare and usually results secondarily from vitamin D deficiency. However, the potential for confounding on the basis of deficiency of other nutrients besides vitamin D makes this disorder a poor model for the study of hypophosphatemia and growth. Among children with X-linked hypophosphatemic rickets, those who initiated treatment with supplemental phosphate and vitamin D before puberty achieved greater mean height SD scores than untreated historical control subjects. Similarly, initiation of treatment before 1 yr of life results in greater height than later treatment. Although an association between hypophosphatemia and short stature and bone health in children with X-linked hypophosphatemic rickets seems plausible, a primary role of hypophosphatemia remains in question given alterations in 1,25 (OH)₂ Vitamin D levels and fibroblast growth factor 23.

It is doubtful that patients with X-linked hypophosphatemic rickets can be generalized to other groups of pediatric patients with hypophosphatemia. Nonetheless, phosphate repletion is widely recommended.

Derangements in serum phosphate are also common in patients with advanced chronic kidney and ESRD. Most often, this manifests as hyperphosphatemia; however, hypophosphatemia related to phosphate binder therapy or nutritional status is not uncommon. One study demonstrated that among patients who had chronic kidney disease and were not yet receiving renal replacement therapy, hypophosphatemia (<0.8 mmol/L) was not associated with increased mortality compared with low-normal serum phosphate (0.8 to 0.93 mmol/L).

Multiple studies have examined the relationship between serum phosphate level and mortality among dialysis-treated patients. One large retrospective cohort study of patients who were treated by a single dialysis provider chain demonstrated a U-shaped unadjusted relationship between serum phosphate level and all-cause mortality. However, on adjustment for case mix, comorbid disease, and nutritional status, lower levels of serum phosphate (<0.96 mmol/L) were no longer associated with increased mortality risk.

US Renal Data System data demonstrate no increased cardiovascular events or adjusted death rates among patients in the lowest quintile of serum phosphate (≤1.4 mmol/L). Unfortunately, no distinction was made between frank hyperphosphatemia and low-normal serum phosphate. Conversely, the multinational Dialysis Outcomes and Practice Patterns Study (DOPPS) found a significant adjusted relationship between hyperphosphatemia (<0.8 mmol/L) and all-cause mortality. Whether the discrepancies between the US Renal Data System and DOPPS data represent differences in the underlying dialysis populations, differences in treatment paradigms, or residual confounding is unclear.

Given that serum phosphate levels are dynamic among dialysis-treated patients, one group used time-varying Cox proportional hazards models to examine the relationship between serum phosphate and all-cause mortality. There was a large unadjusted association between low serum phosphate (<0.96 mmol/L) and mortality (hazard ratio approximately 3.2) that was mitigated but remained statistically significant after adjustment for case mix and markers of the malnutrition-inflammation-cachexia syndrome (hazard ratio approximately 1.4). Overall, there seems to be an association between low and normal serum phosphate and mortality among dialysis-treated patients.

Hypophosphatemia is also very common after kidney transplantation. Initially, this was thought to result from sudden normalization of glomerular filtration in the setting of persistently high levels of parathyroid hormone, relative vitamin D deficiency, and use of glucocorticoids in the immunosuppressive regimen; however, the pathogenic role of phosphatonin has recently come into view. Posttransplantation hypophosphatemia coexists with histologic and radiographic changes in bone mineralization, and increased fracture risk. Whereas surrogate markers of bone and nutritional health (e.g., serum phosphate, parathyroid hormone, osteocalcin, vitamin D levels) normalize in response to phosphate supplementation, no study has found effects on clinical outcomes.

Finally, something in general should be said about phosphate repletion. Most authors recommend oral repletion in ambulatory patients who have chronic hypophosphatemia. A typical regimen is 15 mg/kg oral phosphate, given in three to four divided doses to minimize gastrointestinal adverse effects such as diarrhea and gastric irritation. Often cow milk can be used as a source of oral phosphate. For patients who are unable to tolerate dairy products, there are a number of commercially available preparations of oral sodium and potassium phosphate. We know of no studies that have evaluated the safety and the efficacy of oral phosphate repletion regimens. However, given the relative ease of oral repletion, and considering the absence of data that suggest harm, oral therapy is probably
warranted for most ambulatory patients with hypophosphatemia.

Often, oral phosphate repletion is not feasible in hospitalized patients, particularly the critically ill. Given the potential physiologic benefits of phosphate repletion in these patients, considerable interest has been given to developing safe and efficacious intravenous phosphate repletion regimens.

Complications after overzealous attempts at intravenous phosphate repletion, including renal failure, hypocalcemic tetany, hypotension, hyperphosphatemia, and electrocardiographic abnormalities, led to the development of very conservative regimens. For many years, the standard of care was 0.32 mmol/kg intravenous phosphate administered over 12 h. However, after this protocol, only 58% of treated patients achieved serum phosphate levels >0.64 mmol/L by 24 h.

The lack of efficacy of traditional protocols, along with concerns of compromising intravenous lines during prolonged phosphate infusions, has led to a move toward more aggressive intravenous phosphate repletion regimens. Administration of 15 mmol of intravenous sodium phosphate over 2 h (repeated up to three times over 24 h) is well tolerated. Randomized, controlled trial data suggest equal safety and efficacy of rapid (30 mmol over 2 h and 45 mmol over 3 h for serum phosphate of 0.40 to 0.65 mmol/L and <0.40 mmol/L, respectively) versus conservative phosphate infusions (equivalent doses given over 4 and 6 h, respectively).

Use of a weight- and serum phosphate–based algorithm for intravenous phosphate repletion (Table 3) resulted in significant improvement in the proportion of patients who achieved normal serum phosphate, as compared with historical control subjects who received phosphate repletion via a nonstandardized approach: 76 versus 47%, respectively. The bulk of existing evidence suggests the overall advantage of faster, more aggressive and tailored intravenous phosphate repletion regimens.

### DISCLOSURES

None.

### REFERENCES


---

**Table 3. Phosphorus repletion protocol**

<table>
<thead>
<tr>
<th>Phosphorus Level</th>
<th>Weight 40 to 60 kg</th>
<th>Weight 61 to 80 kg</th>
<th>Weight 81 to 120 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.32 mmol/L</td>
<td>30 mmol Phos IV</td>
<td>40 mmol Phos IV</td>
<td>50 mmol Phos IV</td>
</tr>
<tr>
<td>0.32 to 0.54 mmol/L</td>
<td>20 mmol Phos IV</td>
<td>30 mmol Phos IV</td>
<td>40 mmol Phos IV</td>
</tr>
<tr>
<td>0.58 to 0.70 mmol/L</td>
<td>10 mmol Phos IV</td>
<td>15 mmol Phos IV</td>
<td>20 mmol Phos IV</td>
</tr>
</tbody>
</table>

*Reproduced with permission from Taylor et al. IV, intravenous, Phos, phosphorus. If the patient’s serum potassium is <4.0 mEq/L, then use potassium phosphorus, if the patient’s serum potassium is >4.0 mEq/L, then use sodium phosphorus.*